Eli Radiopharma raises $60M Series A for radiopharma pipeline
What's the deal? Hangzhou Eli RadiopharmaDealroom has a profile for this one. Try Dealroom → has completed a Series A round of nearly US$55M to push its radiopharmaceutical pipeline toward clinical development. Huagai CapitalDealroom has a profile for this one. Try Dealroom → led the round, with Bayland CapitalDealroom has a profile for this one. Try Dealroom → as co-lead and a long list of investors joining, including Boyu Ventures, Delian CapitalDealroom has a profile for this one. Try Dealroom →, and existing backers CSPC & Growth Bio Fund and KHK Fund.
What's the endgame? Eli develops integrated diagnostics and therapeutics for cancer and neurological diseases. It will spend the money on preclinical research, clinical trial applications, early-stage trials, R&D platforms, and hiring. Several programs are approaching IND submission.
Why now? The raise follows roughly US$41.3M in earlier financings, including a near-US$13.8M round in March 2026. "Moving our pipeline toward the clinic is a critical next step," said founder and chief executive officer Feng Yu.
What could go wrong? China's radiopharmaceutical pipeline is large but early-stage, and much of its value hinges on whether candidates can advance clinically and secure isotope supply and commercial partners. Eli's undisclosed lead programs also make its competitive position hard to assess.
The signal: The round sits near the 96th percentile for Series A deals in China's health sector over the past four years, a sign of strong investor appetite. It lands as radiopharmaceuticals draw global interest — Novartis has recently licensed preclinical assets from Chinese developers BoomRay and Zonsen PepLib and invested in local manufacturing. For Eli, the financing is a notable commitment to its next development stage.
Read more: finance.yahoo.com
Image credit: NavyMedicine
